ERBB2 and neoplasm: Interestingly, by using a HER2-negative B7H6-expressing target cell line (K562), we could show that HER2CAR+NKp30+CD8+ T cells could effectively kill HER2-negative target cells contrarily to conventional HER2CAR+NKp30−CD8+ T cells, which were unable to recognize those tumor targets (Figure 5(d)).